BioLife Solutions, Inc. $BLFS Shares Newly Acquired by Transmarket Holdings LP

Transmarket Holdings LP bought a new position in shares of BioLife Solutions, Inc. (NASDAQ:BLFS) during the 3rd quarter, Holdings Channel reports. The institutional investor bought 138,110 shares of the medical equipment provider’s stock, valued at approximately $5,366,000. BioLife Solutions comprises approximately 3.0% of Transmarket Holdings LP’s holdings, making the stock its 6th largest holding.

Other institutional investors have also recently added to or reduced their stakes in the company. Yousif Capital Management LLC boosted its holdings in BioLife Solutions by 4.9% in the third quarter. Yousif Capital Management LLC now owns 11,097 shares of the medical equipment provider’s stock valued at $431,000 after purchasing an additional 520 shares in the last quarter. Kings Path Partners LLC acquired a new stake in BioLife Solutions during the third quarter worth approximately $644,000. Nisa Investment Advisors LLC boosted its holdings in shares of BioLife Solutions by 13.3% in the 3rd quarter. Nisa Investment Advisors LLC now owns 2,209 shares of the medical equipment provider’s stock valued at $86,000 after buying an additional 260 shares in the last quarter. Abel Hall LLC acquired a new position in shares of BioLife Solutions in the 3rd quarter valued at $224,000. Finally, GAMMA Investing LLC boosted its holdings in shares of BioLife Solutions by 7.2% in the 3rd quarter. GAMMA Investing LLC now owns 9,647 shares of the medical equipment provider’s stock valued at $375,000 after buying an additional 651 shares in the last quarter. Hedge funds and other institutional investors own 93.24% of the company’s stock.

BioLife Solutions Price Performance

Shares of BioLife Solutions stock opened at $38.61 on Thursday. BioLife Solutions, Inc. has a 52-week low of $17.86 and a 52-week high of $39.76. The company’s 50-day simple moving average is $37.46 and its 200-day simple moving average is $27.81. The firm has a market cap of $1.89 billion, a price-to-earnings ratio of 33.28 and a beta of 1.82.

BioLife Solutions (NASDAQ:BLFS) last announced its quarterly earnings data on Thursday, August 6th. The medical equipment provider reported $0.91 EPS for the quarter, beating analysts’ consensus estimates of $0.03 by $0.88. The firm had revenue of $28.47 million during the quarter, compared to the consensus estimate of $27.80 million. BioLife Solutions had a net margin of 53.29% and a return on equity of 2.70%. Equities research analysts anticipate that BioLife Solutions, Inc. will post 0.03 EPS for the current year.

Wall Street Analyst Weigh In

A number of research firms recently commented on BLFS. Weiss Ratings raised shares of BioLife Solutions from a “sell (d-)” rating to a “hold (c)” rating in a research report on Tuesday, September 22nd. Zacks Research cut shares of BioLife Solutions from a “strong-buy” rating to a “hold” rating in a research report on Monday, September 21st. William Blair set a $31.00 price objective on shares of BioLife Solutions in a research note on Thursday, July 23rd. Lake Street Capital lowered BioLife Solutions from a “buy” rating to a “hold” rating and dropped their price objective for the stock from $33.00 to $31.00 in a report on Wednesday, July 22nd. Finally, Stephens lowered BioLife Solutions from an “overweight” rating to an “equal weight” rating and dropped their price objective for the stock from $32.00 to $31.00 in a report on Monday, July 27th. One analyst has rated the stock with a Buy rating and ten have assigned a Hold rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $31.38.

BioLife Solutions Profile

BioLife Solutions, Inc develops and supplies products and services used to preserve, process, store and transport biological materials. Its solutions support the development and manufacture of cell and gene therapies, including products designed to help maintain the viability and functionality of cells, tissues and other biologic materials throughout the bioprocessing workflow.

The company’s portfolio includes preservation media such as CryoStor and HypoThermosol, cell thawing and handling products, and related storage and shipping systems.